What happened with TEVA today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Generic medicines account for most of Teva Pharmaceutical Industries’ revenue. These medicines offer chemical and therapeutic equivalents of originator drugs, typically at lower prices. In the United States, Teva sells most of its generics to retail drug chains, mail-order distributors and wholesalers. McKesson and AmerisourceBergen each account for a substantial share of company sales, mostly in the United States, leaving Teva dependent on large buyers’ purchasing decisions and pricing negotiations.
Teva also sells innovative medicines, chiefly in the United States, with a portfolio centered on central nervous system conditions. Growth in this business depends mainly on AUSTEDO, AJOVY and UZEDY. Its Anda business distributes both Teva and other manufacturers’ medicines to pharmacies, hospitals and physician offices.
The generic business depends on pharmacists, insurers and health systems accepting lower-cost substitutes. As competing versions enter, prices fall, making timely new-product launches important. Teva must obtain regulatory approvals, meet ongoing manufacturing and safety standards, and navigate other companies’ patent rights before commercializing products. Government pricing rules and insurers’ coverage and reimbursement decisions also shape what it can earn.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Teva’s broader generics rivals also include Sandoz, Sun Pharmaceuticals and Hikma, none of which appears on this list.
Neurocrine Biosciences’ INGREZZA competes directly with Teva’s AUSTEDO and AUSTEDO XR for adults with tardive dyskinesia and for Huntington’s-related chorea. Watch INGREZZA sales through its U.S. specialty pharmacies and distributors: they show the scale of competition facing AUSTEDO, whose U.S. revenue rose 35% in 2025.
Viatris competes with Teva across broad portfolios of generic and established medicines in the United States and international markets. Its ability to supply tablets, injectables and complex medicines reliably is worth watching alongside Teva’s sales to pharmacy chains and wholesalers.
Dr. Reddy’s competes with Teva on prices, launches and reliable supply in U.S. generics and international branded generics. Watch its first-to-market launches and differentiated medicines against Teva’s generic sales to U.S. drug chains, mail-order distributors and wholesalers.
Amneal Pharmaceuticals, Inc. challenges Teva in retail generics, injectables and biosimilars as both prioritize complex, higher-value launches. Watch new products in Amneal’s Affordable Medicines business, where difficult formulations and manufacturing can create barriers to competing suppliers.
Sanofi and Teva jointly develop duvakitug, so progress on that medicine matters to Teva’s development-milestone revenue. Its move into Phase 3 studies generated substantial milestone revenue for Teva.
Teva depends on Alvotech to develop and manufacture biosimilars that Teva markets and sells in the United States. The products to follow in this partnership are SIMLANDI and their aflibercept program.
Alkermes’ ARISTADA competes with Teva’s UZEDY for long-acting schizophrenia treatment. Watch ARISTADA sales against UZEDY’s U.S. revenue, which grew 63% in 2025 mainly through higher volumes.
Eli Lilly’s Emgality competes with Teva’s AJOVY for preventive migraine treatment, making Emgality the Lilly product to watch for this part of Teva’s business.
AbbVie competes with Teva on two fronts: its migraine medicines face AJOVY, while Humira faces Teva’s similar biological medicine SIMLANDI, a biosimilar.
Amgen’s Aimovig competes with Teva’s AJOVY in migraine prevention; both companies also market biosimilars. Aimovig is the clearest product to follow for their direct rivalry.
Biogen’s multiple-sclerosis medicines compete with Teva’s COPAXONE, while Teva’s Truxima competes with RITUXAN, in which Biogen has financial rights rather than handling sales and distribution. Watch Biogen’s multiple-sclerosis sales alongside COPAXONE, whose U.S. and European market share declined during 2025 as newer treatments gained adoption.
McKesson is both a major buyer of Teva medicines and a rival to Teva’s Anda business in supplying pharmacies and other healthcare customers; it accounted for 13% of Teva’s consolidated third-party net sales in 2025, mostly in the U.S. segment. Watch its pharmacy-distribution business alongside Anda’s third-party revenue, which fell 3% in 2025 mainly on lower volumes.
Dr. Reddy's Laboratories Limited earningsRDY
Dr. Reddy's report will show whether a direct rival in U.S. generics and international branded generics is winning sales with launches or mainly competing on price.
Watch Dr. Reddy's sales from new launches alongside its generic business, and whether pricing weakens as competition grows. Launch-led sales without clear price deterioration would suggest Teva can also compete through new and differentiated products; weak sales or mounting price pressure would make Teva's generic margins harder to defend.
Alkermes Inc. plc earningsALKS
Alkermes' report will show how ARISTADA is selling in long-acting schizophrenia treatment, where Teva's UZEDY also competes for patients.
Watch ARISTADA sales alongside Teva's U.S. sales of UZEDY. Stronger ARISTADA sales would signal tougher competition in the same treatment market and a harder fight for UZEDY; weaker sales would suggest less pressure from this rival, but would not prove UZEDY is winning more business.
Biogen Inc. earningsBIIB
Biogen's report will show how its multiple-sclerosis medicines are selling in a market where newer treatments have pressured Teva's COPAXONE.
Compare Biogen's multiple-sclerosis sales with Teva's COPAXONE sales and market-share trend. Strong Biogen sales, especially alongside continued uptake of newer treatments, would indicate sustained substitution pressure on COPAXONE; weaker Biogen sales could mean less competitive pressure, but COPAXONE would still need to show that it can hold its ground.
Eli Lilly & Co. earningsLLY
Lilly's report will show how Emgality is selling in preventive migraine treatment, where Teva's AJOVY competes for patients.
Read Lilly's Emgality sales alongside Teva's AJOVY sales. Stronger Emgality sales would point to tougher competition for patients in preventive migraine treatment and a harder market for AJOVY; weaker sales would suggest less pressure from this rival, but would not show that AJOVY is growing.
ABBVIE INC. earningsABBV
AbbVie's report will show how Humira is selling against SIMLANDI, the biosimilar medicine Teva markets to compete in the same market.
Compare Humira's sales trend with Teva's sales of SIMLANDI. Resilient Humira sales would show that the established brand remains a strong rival and that SIMLANDI has a hard job winning patients; weaker Humira sales could lower that hurdle, but SIMLANDI would still need to turn the opening into sales.
Sanofi earningsSNY
If Sanofi reports on duvakitug's development, its report will show whether the joint program with Teva may be moving toward another milestone that could generate licensing income.
Watch for Sanofi's update on duvakitug's development, and distinguish it from the licensing income Teva previously recorded when Phase 3 studies began. Continued progress would leave open the possibility of another development milestone and related licensing income; a delay or setback would make that potential less certain, and the earlier milestone should not be mistaken for recurring product sales.
Neurocrine Biosciences Inc earningsNBIX
Neurocrine Biosciences' report will show how INGREZZA is selling in treatment markets shared with AUSTEDO, a major Teva product in the United States.
Read INGREZZA sales alongside Teva's U.S. AUSTEDO sales. Stronger INGREZZA sales would signal more competition in the markets for tardive dyskinesia and Huntington's-related chorea, putting greater pressure on an important source of Teva revenue; weaker sales would suggest less pressure from this rival, but would not prove AUSTEDO is gaining share.
Teva Pharmaceutical Industries Limited earningsThis company
Teva's report will show whether sales of medicines such as AUSTEDO can keep improving its product mix enough to offset pressure on generics and distribution.
Read sales of AUSTEDO, AJOVY and UZEDY alongside gross margin, and separate any boost from development-milestone income, which may not recur. Stronger product sales with a firm margin would show higher-margin medicines supporting the business; if milestones do most of the lifting, or product sales and margin weaken, generic price pressure and softer Anda distribution remain a drag on Teva.
McKesson Corporation earningsMCK
McKesson is both a major buyer of Teva medicines and a drug distributor, so its report gives a channel comparison for Teva's Anda distribution business.
Compare McKesson's pharmacy-distribution business with revenue from Teva's Anda third-party distribution. If McKesson's channel is firm while Anda weakens, Teva's own distribution business may be losing ground; if both weaken, softer pharmacy-channel demand is a more plausible concern. McKesson does not disclose its purchases from Teva specifically, so this comparison is context, not proof of a change in Teva's sales to McKesson.
Alvotech earningsALVO
Alvotech develops and manufactures biosimilars Teva sells in the United States, so its report could reveal progress or setbacks for SIMLANDI and the aflibercept program.
Watch Alvotech's updates on development and manufacturing for SIMLANDI and its aflibercept program. Progress would support Teva's ability to keep developing and selling these biosimilars; delays or manufacturing setbacks would matter because Teva depends on this partner, putting product supply and the related sales opportunity at risk.
